Screener
Viking Therapeutics VKTX Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 9:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-193315
| Revenues | Three Months Ended March 31, 2026 / — | Three Months Ended March 31, 2025 / — |
|---|---|---|
| Total other income, net | 5,800 | 9,840 |
| Net loss | (158,325) | (45,629) |
| Other comprehensive loss, net of tax: | ||
| Unrealized (loss) gain on securities | (1,250) | 563 |
| Foreign currency translation gain | 16 | 9 |
| Comprehensive loss | $(159,559) | $(45,057) |
| Basic and diluted net loss per share | $(1.37) | $(0.41) |
| Weighted-average shares used to compute basic and diluted net loss per share | 115,568 | 112,069 |
Item 1. Financial Statements
FAQ
- What is Viking Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
- Viking Therapeutics (VKTX) reported comprehensive income (loss), net of tax, attributable to parent of -$159.56M in Q1 2026.
- How has Viking Therapeutics's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Viking Therapeutics's comprehensive income (loss), net of tax, attributable to parent decreased by 254.1% year-over-year, from -$45.06M to -$159.56M.
- What is the long-term trend for Viking Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
- Over 4 years (2021 to 2025), Viking Therapeutics's comprehensive income (loss), net of tax, attributable to parent has grown at a 59.4% compound annual growth rate (CAGR), from -$55.49M to -$358.47M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This metric represents the total change in equity from non-owner sources, encompassing both net income and other comprehensive income items such as unrealized gains or losses on securities and foreign currency adjustments. It provides a comprehensive view of the company's financial performance beyond traditional net income. Investors use this to assess the total impact of all economic events on the company's equity base.
Ask your AI about Viking Therapeutics's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude